KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $137.0 million.

  • Sarepta Therapeutics' Capital Expenditures fell 38.45% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.5 million, marking a year-over-year increase of 15.73%. This contributed to the annual value of $137.0 million for FY2024, which is 79.95% up from last year.
  • Sarepta Therapeutics' Capital Expenditures amounted to $137.0 million in FY2024, which was up 79.95% from $76.1 million recorded in FY2023.
  • Over the past 5 years, Sarepta Therapeutics' Capital Expenditures peaked at $137.0 million during FY2024, and registered a low of $30.8 million during FY2022.
  • Over the past 3 years, Sarepta Therapeutics' median Capital Expenditures value was $76.1 million (recorded in 2023), while the average stood at $81.3 million.
  • In the last 5 years, Sarepta Therapeutics' Capital Expenditures plummeted by 53.18% in 2021 and then surged by 146.91% in 2023.
  • Sarepta Therapeutics' Capital Expenditures (Yearly) stood at $82.2 million in 2020, then tumbled by 53.18% to $38.5 million in 2021, then fell by 19.92% to $30.8 million in 2022, then surged by 146.91% to $76.1 million in 2023, then soared by 79.95% to $137.0 million in 2024.